SERPINE1: Role in Cholangiocarcinoma Progression and a Therapeutic Target in the Desmoplastic Microenvironment
Abstract
:1. Introduction
2. The Desmoplastic Tumor Microenvironment in CCA
3. CAF Subtypes in Cholangiocarcinoma
4. Signaling Pathways Involved in CCA Desmoplasia
5. Multifunctional Impact of PAI-1 on Cholangiocarcinoma Progression
6. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Zabron, A.; Edwards, R.J.; King, S.A. The challenge of cholangocarcinoma: Dissecting the molecular mechanisms of an insidious cancer. Dis. Models Mech. 2013, 6, 281–292. [Google Scholar] [CrossRef] [PubMed]
- Brindley, P.J.; Bachini, M.; Illyas, S.I.; Khan, S.A.; Loukas, A.; Sirica, A.E.; Teh, B.T.; Wongkham, S.; Cores, G.J. Cholangiocarcinoma. Nat. Rev. (Dis. Primers) 2012, 7, 6. [Google Scholar] [CrossRef] [PubMed]
- Yang, S.; Zou, R.; Dai, Y.; Hu, Y.; Li, F.; Hu, H. Tumor immune microenvironment and the current immunotherapy of cholangiocarcinoma (review). Int. J. Oncol. 2023, 63, 137. [Google Scholar] [CrossRef] [PubMed]
- Seol, M.-A.; Chu, I.-S.; Lee, J.-J.; Yu, G.-R.; Cui, X.D.; Cho, B.-H.; Ahn, E.-K.; Leem, S.-H.; Kim, I.-H.; Kim, D.-G. Genome-wide expression patterns associated with oncogenesis and sarcomatous transdifferentation of cholangiocarcinoma. BMS Cancer 2011, 11, 78. [Google Scholar] [CrossRef] [PubMed]
- Gopal, P.; Robert, M.E.; Zhang, X. Cholangiocarcinoma: Pathologic and molecular classification in the era of precision medicine. Arch. Pathol. Lab. Med. 2023, 148, 359–370. [Google Scholar] [CrossRef] [PubMed]
- Jusakul, A.; Cutchtache, I.; Yong, C.H.; Lim, J.Q.; Huang, M.N.; Padmanabhan, N.; Nellore, V.; Kongpetch, S.; Ng, A.W.T.; Ng, L.M.; et al. Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma. Cancer Discov. 2017, 7, 1116–1135. [Google Scholar] [CrossRef] [PubMed]
- Li, H.; Qu, L.; Zhang, H.; Liu, J.; Zhang, X. A comprehensive transcriptomic landscape of cholangiocarcinoma based on bioinformatics analysis from large cohort of patients. Sci. Rep. 2021, 11, 13713. [Google Scholar] [CrossRef]
- Li, H.; Qu, L.; Yang, Y.; Zhang, H.; Li, X.; Zhang, X. Single-cell transcriptomic architecture unraveling the complexity of tumor heterogeneity in distal cholangiocarcinoma. Cell. Mol. Gastroenterol. Hepatol. 2022, 13, 1592–1609. [Google Scholar] [CrossRef] [PubMed]
- Valle, J.W.; Kelley, R.K.; Nervi, B.; Oh, D.-Y.; Zhu, A.X. Biliary tract cancer. Lancet 2021, 397, 428–444. [Google Scholar] [CrossRef] [PubMed]
- Vauthey, J.N.; Blumgart, L.H. Recent advances in the management of cholangiocarcinomas. Semin. Liver Dis. 1994, 14, 109–114. [Google Scholar] [CrossRef]
- Ioka, T.; Shindo, Y.; Ueno, M.; Nagano, H. Current progress in perioperative chemotherapy for biliary tract cancer. Ann. Gastroenterol. Surg. 2023, 7, 565–571. [Google Scholar] [CrossRef] [PubMed]
- Pavicevic, S.; Reichelt, S.; Uluk, D.; Lurje, I.; Engelmann, C.; Modest, D.P.; Pelzer, U.; Krenzien, F.; Raschzok, N.; Benzing, C.; et al. Prognostic and predictive molecular markers in cholangiocarcinoma. Cancers 2022, 14, 1026. [Google Scholar] [CrossRef] [PubMed]
- Jalil, A.T.; Abdulhadi, M.A.; Al-Ameer, L.R.; Khaleel, L.A.; Abdulameer, S.J.; Hadi, A.M.; Merza, M.S.; Zabibah, R.S. Small but mighty: How microRNAs drive the deadly progression of cholangiocarcinoma. Pathol. Res. Pract. 2023, 247, 154565. [Google Scholar] [CrossRef] [PubMed]
- Kendall, T.; Verheij, J.; Gaudio, E.; Evert, M.; Guido, M.; Goeppert, B.; Carpino, G. Anatomical histomorphological and molecular classification of cholangiocarcinoma. Liver Int. 2019, 39 (Suppl. S1), 7–18. [Google Scholar] [CrossRef] [PubMed]
- Sadot, E.; Simpson, A.L.; Do, R.K.G.; Gonen, M.; Shia, J.; Allen, P.J.; D’Angelica, M.I.; DeMatteo, R.P.; Kingham, T.P.; Jarnagin, W.R. Cholangiocarcinoma: Correlation between molecular profiling and imaging phenotypes. PLoS ONE 2015, 10, e0132953. [Google Scholar] [CrossRef]
- Chen, C.; Nelson, L.J.; Avila, M.A.; Cubero, F.J. Mitogen-activated protein kinases (MAPKs) and cholangiocarcinoma: The missing link. Cells 2019, 8, 1172. [Google Scholar] [CrossRef]
- Banales, J.M.; Marin, J.J.G.; Lamarca, A.; Rodrigues, P.M.; Kan, S.A.; Roberts, L.R.; Cardinale, V.; Carpino, G.; Andersen, J.B.; Braconi, C.; et al. Cholangiocarcinoma 2020: The next horizon in mechanisms and management. Nat. Rev. Gastroenterol. Hepatol. 2020, 17, 557–588. [Google Scholar] [CrossRef]
- Sripa, B.; Bethony, J.M.; Sithithaworn, P.; Kaewkes, S.; Mairiang, E.; Loukas, A.; Mulvenna, J.; Laha, T.; Hotez, P.J.; Brindley, P.J. Opisthorchiasis and opisthorchis-associated cholangiocarcinoma in Thailand and Laos. Acta Trop. 2011, 120 (Suppl. S1), S158–S168. [Google Scholar] [CrossRef] [PubMed]
- Affo, S.; Yu, L.-X.; Schwabe, R.F. The role of cancer-associated fibroblasts and fibrosis in liver cancer. Annu. Rev. Pathol. Mech. Dis. 2017, 12, 153–186. [Google Scholar] [CrossRef] [PubMed]
- Kawamura, E.; Matsubara, T.; Kawada, N. New era of immune-based therapy in intrahepatic cholangiocarcinoma. Cancers 2023, 15, 3993. [Google Scholar] [CrossRef] [PubMed]
- Sato, K.; Baiocchi, L.; Kennedy, L.; Zhang, W.; Ekser, B.; Glaser, S.; Francis, H.; Alpini, G. Current advances in basic and translation research of cholangiocarcinoma. Cancers 2021, 13, 3307. [Google Scholar] [CrossRef] [PubMed]
- Barsky, S.H.; Green, W.R.; Grotendorst, G.R.; Liotta, L.A. Desmoplastic breast carcinoma as a source of human myofibroblasts. Am. J. Pathol. 1984, 115, 329–333. [Google Scholar] [PubMed]
- LeBleu, V.S.; Kalluri, R. A peek into cancer-associated fibroblasts: Origins, functions and translational impact. Dis. Model Mech. 2018, 11, dmm029447. [Google Scholar] [CrossRef] [PubMed]
- Biffi, G.; Tuveson, D.A. Diversity and biology of cancer-associated fibroblasts. Physiol. Rev. 2021, 101, 147–176. [Google Scholar] [CrossRef]
- Liu, T.; Zhou, L.; Li, D.; Andl, T.; Zhang, Y. Cancer-associated fibroblasts build and secure the tumor microenvironment. Front. Cell Dev. Biol. 2019, 7, 60. [Google Scholar] [CrossRef] [PubMed]
- Chen, X.; Song, E. Turning foes to friends: Targeting cancer-associated fibroblasts. Nat. Rev. Drug Discov. 2019, 18, 99–115. [Google Scholar] [CrossRef]
- Denton, A.C.; Roberts, E.W.; Fearon, D.T. Stroma cells in the tumor microenvironment. Adv. Exp. Med. Biol. 2018, 1060, 99–114. [Google Scholar] [PubMed]
- Mao, Y.; Keller, E.T.; Garfield, D.H.; Shen, K.; Wang, J. Stromal cells in tumor microenvironment and breast cancer. Cancer Metastasis Rev. 2013, 32, 303–315. [Google Scholar] [CrossRef] [PubMed]
- Kim, I.; Choi, S.; Yoo, S.; Lee, M.; Kim, I.-S. Cancer associated fibroblasts in the hypoxic tumor microenvironment. Cancers 2022, 14, 3321. [Google Scholar] [CrossRef] [PubMed]
- Ying, F.; Chan, M.S.M.; Lee, T.K.W. Cancer-associated fibroblasts in hepatocellular carcinoma and cholangiocarcinoma. Cell. Mol. Gastroenterol. Hepatol. 2023, 15, 985–999. [Google Scholar] [CrossRef] [PubMed]
- Vonlaufen, A.; Phillips, P.A.; Xu, Z.; Goldstein, D.; Pirola, R.C.; Wilson, J.S.; Apte, M.V. Pancreatic stellate cells and pancreatic cancer cells: An unholy alliance. Cancer Res. 2008, 68, 7707–7710. [Google Scholar] [CrossRef] [PubMed]
- Ezhilarasan, D. Hepatic stellate cells in the injured liver: Perspectives beyond hepatic fibrosis. J. Cell. Physiol. 2022, 237, 436–449. [Google Scholar] [CrossRef] [PubMed]
- Helms, E.J.; Berry, M.W.; Chaw, R.C.; DuFort, C.C.; Sun, D.; Onate, M.K.; Oon, C.; Bhattacharyya, S.; Sanford-Crane, H.; Horton, W.; et al. Mesenchymal lineage heterogeneity underlies nonredundant functions of pancreatic cancer-associated fibroblasts. Cancer Discov. 2022, 12, 484–501. [Google Scholar] [CrossRef] [PubMed]
- Zhang, M.; Yang, H.; Wan, L.; Wang, Z.; Wang, H.; Ge, C.; Liu, Y.; Hao, Y.; Zhang, D.; Shi, G.; et al. Single-cell transcriptomic architecture and intercellular crosstalk of human intrahepatic cholangiocarcinoma. J. Hepatol. 2020, 73, 1118–1130. [Google Scholar] [CrossRef] [PubMed]
- Vaquero, J.; Aoudjehane, L.; Fouassier, L. Cancer-associated fibroblasts in cholangiocarcinoma. Curr. Opin. Gastroenterol. 2020, 36, 63–69. [Google Scholar] [CrossRef] [PubMed]
- Yoshida, Y.; Nakanishi, Y.; Mitsuhashi, T.; Yamamoto, H.; Hayashi, M.O.; Oba, M.; Nitta, T.; Ueno, T.; Yamada, T.; Ono, M.; et al. Postoperative prognosis according to pathologic categorization of desmoplastic reaction in patients with extrahepatic cholangiocarcinoma. Ann. Surg. Oncol. 2023, 30, 7348–7357. [Google Scholar] [CrossRef] [PubMed]
- Chuaysri, C.; Thuwajit, P.; Paupairoj, A.; Chau-In, S.; Suthiphongchai, T.; Thuwajit, C. Alpha-smooth muscle actin-positive fibroblasts promote biliary cell proliferation and correlate with poor survival in cholangiocarcinoma. Oncol. Rep. 2009, 21, 957–969. [Google Scholar] [PubMed]
- Gundlach, J.-P.; Kerber, J.; Hendricks, A.; Bernsmeier, A.; Halske, C.; Roder, C.; Becker, T.; Rocken, C.; Braun, R.; Sebens, S. Paracrine interaction of cholangiocellular carcinoma with cancer-associated fibroblasts and Schwann cells impact cell migration. J. Clin. Med. 2022, 11, 2785. [Google Scholar] [CrossRef] [PubMed]
- Vita, F.; Olaizola, I.; Amato, F.; Rae, C.; Marco, S.; Banales, J.M.; Craconi, C. Heterogeneity of cholangiocarcinoma immune biology. Cells 2023, 12, 846. [Google Scholar] [CrossRef] [PubMed]
- Lin, J.; Dai, Y.; Sang, C.; Song, G.; Xiang, B.; Zhang, M.; Dong, L.; Xia, X.; Ma, J.; Shen, X.; et al. Multimodule characterization of immune subgroups in intrahepatic cholangiocarcinoma reveals distinct therapeutic vulnerabilities. J. Immunother. Cancer 2022, 10, e004892. [Google Scholar] [CrossRef]
- DeFilippis, R.A.; Chang, C.; Dumont, N.; Rabban, J.T.; Chen, Y.-Y.; Fontenay, G.V.; Berman, H.K.; Gauthier, M.L.; Zhao, J.; Hu, D.; et al. CD36 represssion activates a multicellular stromal program shared by high mammographic density and tumor tissues. Cancer Discov. 2012, 2, 826–839. [Google Scholar] [CrossRef] [PubMed]
- DeClerck, Y.A. Desmoplasia: A response or a niche? Cancer Discov. 2012, 2, 772–774. [Google Scholar] [CrossRef]
- Biffi, G.; Oni, T.E.; Spielman, B.; Hao, Y.; Elyada, E.; Park, Y.; Preall, J.; Tuveson, D.A. Il1-induced jak/stat signaling is antagonized by TGFβ to shape caf heterogeneity in pancreatic ductal adenocarcinoma. Cancer Discov. 2019, 9, 282–301. [Google Scholar] [CrossRef] [PubMed]
- Yang, D.; Liu, J.; Qian, H.; Zhuang, Q. Cancer associated fibroblasts: From basic science to anticancer therapy. Exp. Mol. Med. 2023, 55, 1322–1332. [Google Scholar] [CrossRef] [PubMed]
- Affo, S.; Nair, A.; Brundu, F.; Ravichandra, A.; Bhattacharjee, S.; Matsuda, M.; Chin, L.; Filliol, A.; Wen, W.; Song, X.; et al. Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations. Cancer Cell 2021, 39, 866–882. [Google Scholar] [CrossRef] [PubMed]
- Knipper, K.K.; Lyu, S.I.; Quaas, A.; Bruns, C.J.; Schmidt, T. Cancer-associated fibroblast heterogeneity and its influence on the extracellular matrix and the tumor microenvironment. Int. J. Mol. Sci. 2023, 24, 13482. [Google Scholar] [CrossRef] [PubMed]
- Nallanthighal, S.; Heiserman, J.P.; Cheon, D.-J. The role of the extracellular matrix in cancer stemness. Front. Cell Dev. Biol. 2019, 7, 86. [Google Scholar] [CrossRef] [PubMed]
- Joshi, R.S.; Kanugula, S.S.; Sudhir, S.; Pereira, M.P.; Jain, S.; Aghi, M.K. The role of cancer-associated fibroblasts in tumor progression. Cancers 2021, 13, 1399. [Google Scholar] [CrossRef]
- Czekay, R.-P.; Cheon, D.-J.; Samarakoon, R.; Kutz, S.M.; Higgins, P.J. Cancer-associated fibroblasts: Mechanisms of tumor progression and novel therapeutic targets. Cancers 2022, 14, 1231. [Google Scholar] [CrossRef] [PubMed]
- Fang, Z.; Meng, Q.; Xu, J.; Wang, W.; Zhang, B.; Liu, J.; Liang, C.; Hua, J.; Zhao, Y.; Yu, X.; et al. Signaling pathways in cancer-associated fibroblasts: Recent advances and future perspectives. Cancer Commun. 2023, 43, 3–41. [Google Scholar] [CrossRef]
- Öhlund, D.; Elyada, E.; Tuveson, D. Fibroblast heterogeneity in the cancer wound. J. Exp. Med. 2014, 21, 1503–1523. [Google Scholar] [CrossRef]
- Kalluri, R. The biology and function of fibroblasts in cancer. Nat. Rev. Cancer 2016, 16, 582–598. [Google Scholar] [CrossRef] [PubMed]
- Parker, A.L.; Bowman, E.; Zingone, A.; Ryan, B.M.; Cooper, W.A.; Kohonen-Corish, M.; Harris, C.C.; Cox, T.R. Extracellular matrix profiles determine risk and prognosis of the squamous cell carcinoma subtype of non-small cell lung carcinoma. Genome Med. 2022, 14, 126. [Google Scholar] [CrossRef] [PubMed]
- Raskov, H.; Orhan, A.; Gaggar, S.; Gogenur, I. Cancer-associated fibroblasts and tumor-associated macrophages in cancer and cancer immunotherapy. Front. Oncol. 2021, 11, 668731. [Google Scholar] [CrossRef]
- Huang, T.-X.; Guan, X.-Y.; Fu, L. Therapeutic targeting of the crosstalk between cancer-associated fibroblasts and cancer stem cells. Am. J. Cancer Res. 2019, 9, 1889–1904. [Google Scholar] [PubMed]
- Ganguly, D.; Chandra, R.; Karalis, J.; Teke, M.; Aguilera, T.; Maddipati, R.; Wachsmann, M.B.; Ghersi, D.; Siravegna, G.; Zeh, H.J., III; et al. Cancer-associated fibroblasts: Versatile players in the tumor microenvironment. Cancers 2020, 12, 2652. [Google Scholar] [CrossRef]
- Shi, X.; Young, C.D.; Zhou, H.; Wang, X.-J. Transforming growth factor-β signaling in fibrotic diseases and cancer-associated fibroblasts. Biomolecules 2020, 10, 1666. [Google Scholar] [CrossRef] [PubMed]
- Noguchi, S.; Saito, A.; Nagase, T. Yap/taz signaling as a molecular link between fibrosis and cancer. Int. J. Mol. Sci. 2018, 19, 3674. [Google Scholar] [CrossRef]
- Piersma, B.; Bank, R.A.; Boersema, M. Signaling in fibrosis: TGF-β, wnt, and yap/taz converge. Front. Med. 2015, 2, 59. [Google Scholar] [CrossRef] [PubMed]
- Mallikarjuna, P.; Raviprakash, T.S.; Aripaka, K.; Ljungberg, B.; Landstrom, M. Interactions between TGF-β type i receptor and hypoxia-inducible factor-a mediates a synergistic crosstalk leading to poor prognosis for patients with clear cell renal cell carcinoma. Cell Cycle 2019, 18, 2141–2156. [Google Scholar] [CrossRef] [PubMed]
- Arima, Y.; Matsueda, S.; Saya, H. Significance of cancer-associated fibroblasts in the interactions of cancer cells with the tumor microenvironment of heterogeneous tumor tissue. Cancers 2023, 15, 2536. [Google Scholar] [CrossRef]
- Gifford, C.C.; Lian, F.; Tang, J.; Costello, A.; Goldschmeding, R.; Samarakoon, R.; Higgins, P.J. PAI-1 induction during kidney injury promotes fibrotic epithelial dysfunction via deregulation of klotho, p53, and TGF-β-receptor signaling. FASEB J. 2021, 35, e21725. [Google Scholar] [CrossRef] [PubMed]
- Papoutsoglou, P.; Louis, C.; Coulouarn, C. Transforming growth factor beta (TGFβ) signaling pathway in cholangiocarcinoma. Cells 2019, 8, 960. [Google Scholar] [CrossRef] [PubMed]
- Merdrignac, A.; Angenard, G.; Allain, C.; Petijean, K.; Bergeat, D.; Belaud, P.; Fautrel, A.; Turlin, B.; Clement, B.; Dooley, S.; et al. A novel transforming growth factor beta-induced long noncoding RNA promotes an inflammatory microenvironment in human intrahepatic cholangiocarcinoma. Hepatol. Commun. 2018, 2, 254–269. [Google Scholar] [CrossRef] [PubMed]
- Li, L.; Li, F.; Xu, Z.; Li, L.; Hu, H.; Li, Y.; Yu, S.; Wang, M.; Gao, L. Identification and validation of SEPINE1 as a prognostic and immunological biomarker in pan-cancer and in ccRCC. Front. Pharmacol. 2023, 14, 1213891. [Google Scholar] [CrossRef] [PubMed]
- Freytag, J.; Wilkins-Port, C.E.; Higgins, C.E.; Carlson, J.A.; Noel, A.; Foidart, J.-M.; Higgins, S.P.; Samarakoon, R.; Higgins, P.J. PAI-1 regulates the invasive phenotype in human cutaneous squamous cell carcinoma. J. Oncol. 2009, 2009, 963209. [Google Scholar] [CrossRef] [PubMed]
- Wei, W.-F.; Zhou, H.-L.; Che, P.-Y.; Huang, X.-L.; Huang, L.; Liang, L.-J.; Guo, C.-H.; Zhou, C.-F.; Yu, L.; Fan, S.-S.; et al. Cancer associated fibroblast-derived PAI-1 promotes lymphatic metastasis via the induction of EndoMT in lymphatic endothelial cells. J. Exp. Clin. Cancer Res. 2023, 42, 160. [Google Scholar] [CrossRef] [PubMed]
- Sakamoto, H.; Koma, Y.i.; Higashino, N.; Kodama, T.; Tanigawa, K.; Shimizu, M.; Fujikawa, M.; Nisho, M.; Shigeoka, M.; Kakeji, Y.; et al. PAI-1 derived from cancer-associated fibroblasts in esophageal squamous cell carcinoma promotes the invasion of cancer cells and the migration of macrophages. Lab. Investig. 2021, 101, 353–368. [Google Scholar] [CrossRef] [PubMed]
- Cartier-Michaud, A.; Malo, M.; Charriere-Bertrand, C.; Gadea, G.; Anguille, C.; Supiramaniam, A.; Lesne, A.; Delaplace, F.; Hutzler, G.; Roux, P.; et al. Matrix-bound PAI-1 supports cell blebbing via RhoA/ROCK1 signaling. PLoS ONE 2012, 7, e32204. [Google Scholar] [CrossRef]
- Higgins, C.E.; Tang, J.; Mian, B.M.; Higgins, S.P.; Gifford, C.C.; Conti, D.J.; Meldrum, K.K.; Samarakoon, R.; Higgins, P.J. TGF-β1-p53 cooperativity regulates a profibrotic genomic program in the kidney: Molecular mechanisms and clinical implications. FASEB J. 2019, 33, 10596–10606. [Google Scholar] [CrossRef]
- Anorga, S.; Overstreet, J.M.; Falke, L.; Tang, J.; Goldschmeding, R.G.; Higgins, P.J.; Samarakoon, R. Deregulation of hippo-taz pathway during renal injury confers a fibrotic maladaptive phenotype. FASEB J. 2018, 32, 2644–2657. [Google Scholar] [CrossRef] [PubMed]
- Chin, Y.R.; Toker, A. Function of Akt/PKB signaling to cell motility, invasion and the tumor stroma in cancer. Cell. Signal. 2009, 21, 470–476. [Google Scholar] [CrossRef] [PubMed]
- Wang, J.; Wsang, X.; Xie, S.; Yan, Z.; Li, Z.; Li, Y.; Wang, L.; Jiao, F. p53 status and its prognostic role in extrahepatic bile duct cancer: A meta-analysis of published studies. Dig. Dic. Sci. 2011, 56, 655–662. [Google Scholar] [CrossRef] [PubMed]
- Bartheja, N.; Suriawinata, A.; Saxena, R.; Ionescu, G.; Schwartz, M.; Thung, S.N. Expression of p53 and PCNA in cholangiocarcinoma and primary sclerosing cholangitis. Mod. Pathol. 2000, 13, 1265–1268. [Google Scholar] [CrossRef] [PubMed]
- Khan, S.A.; Thomas, H.C.; Toledano, M.B.; Cox, I.J.; Taylor-Ribonson, S.D. p53 mutations in human cholangiocarcinoma: A review. Liver Int. 2005, 25, 704–716. [Google Scholar] [CrossRef] [PubMed]
- Overstreet, J.M.; Samarakoon, R.; Meldrum, K.K.; Higgins, P.J. Redox control of p53 in the transcriptional regulation of TGF-β1 target genes through SMAD cooperativity. Cell. Signal. 2014, 26, 1427–1436. [Google Scholar] [CrossRef] [PubMed]
- Horikawa, I.; Park, K.-Y.; Isogaya, Y.; Hiyosh, Y.; Li, H.; Anami, K.; Robles, A.I.; Mondal, A.M.; Fujita, K.; Serrano, M.; et al. Δ133p53 represses p53-inducible senescence genes and enhances the generation of human induced pluripotent stem cells. Cell Death Differ. 2017, 24, 1017–1028. [Google Scholar] [CrossRef] [PubMed]
- Samarakoon, R.; Dobberfuhl, A.D.; Cooley, C.; Overstreet, J.M.; Patel, S.; Goldschmeding, R.; Meldrum, K.K.; Higgins, P.J. Induction of renal fibrotic genes by TGF-β1 requires EGFR activation, p53 and reactive oxygen species. Cell. Signal. 2013, 25, 198–209. [Google Scholar] [CrossRef] [PubMed]
- Higgins, S.P.; Tang, Y.; Higgins, C.E.; Mian, B.; Zhang, W.; Czekay, R.-P.; Samarakoon, R.; Conti, D.J.; Higgins, P.J. TBG-β1/p53 signaling in renal fibrogenesis. Cell. Signal. 2018, 43, 1–10. [Google Scholar] [CrossRef] [PubMed]
- Kortlever, R.M.; Higgins, P.J.; Bernards, R. Plasminogen activator inibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat. Cell Biol. 2006, 8, 877–884. [Google Scholar] [CrossRef] [PubMed]
- Wu, G.; Nomoto, S.; Hoque, M.O.; Dracheva, T.; Osad, M.; Lee, C.-C.R.; Dong, S.M.; Guo, Z.; Benoit, N.; Cohen, Y. ΔNp63α and Tap63α regulate transcription of genes with distinct biological functions in cancer and development. Cancer Res. 2003, 63, 2351–2357. [Google Scholar] [PubMed]
- Perez, C.A.; Ott, J.; Mays, D.J.; Pietenpol, J.A. p63 consensus DNA-binding site: Identification, analysis and application into a p63MH algorithm. Oncogene 2007, 26, 7363–7370. [Google Scholar] [CrossRef] [PubMed]
- Si, H.; Lu, H.; Yang, X.; Mattox, A.; Jang, M.; Bian, Y.; Sano, E.; Viadiu, H.; Yan, B.; Yau, C.; et al. TNF-α modulates genome-wide redistribution of ΔNp63α/Tap73 and NF-κB cREL interactive binding on TP53 and AP-1 motifs to promote an oncogenic gene program in squamous cancer. Oncogene 2016, 35, 5781–5794. [Google Scholar] [CrossRef] [PubMed]
- Nutthasirikul, N.; Limpaiboon, T.; Leelayuwat, C.; Patrakitkomjorn, S.; Jearanaikoon, P. Ratiodisrution of the Δ133p53 and Tap53 isoform equilibrium correlates with poor clinical outcome in intrahepatic cholangiocarcinoma. Int. J. Oncol. 2013, 42, 1181–1188. [Google Scholar] [CrossRef]
- Liu, F.; Lagares, D.; Cho, K.M.; Stopfer, L.; Marinkovic, A.; Vrbanac, V.; Probst, C.K.; Hiemer, S.E.; Sisson, T.H.; Horowitz, J.C.; et al. Mechanosignaling through Yap and Taz drives fibroblast activation and fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 2015, 308, L344–L357. [Google Scholar] [CrossRef] [PubMed]
- Bessho, R.; Takiyama, Y.; Takiyama, T.; Kitsunai, H.; Takeda, Y.; Sakagami, H.; Ota, T. Hypoxia-inducible factor-1α is the therapeutic target of the SGLT2 inhibitor for diabetic nephropathy. Sci. Rep. 2019, 9, 14754. [Google Scholar] [CrossRef] [PubMed]
- Jorgenson, A.J.; Choi, K.M.; Sicard, D.; Smith, K.M.J.; Hiemer, S.F.; Vareles, X.; Tschumperlin, D.T. TAZ activation drives fibroblast spheroid growth, expression of profibrotic paracrine signals, and context-dependent ECM gene expression. Am. J. Physiol. Cell Physiol. 2017, 312, C277–C285. [Google Scholar] [CrossRef] [PubMed]
- Kong, H.-J.; Kwon, E.-J.; Kwon, O.-K.; Lee, H.; Choi, J.-Y.; Kim, Y.-J.; Kim, W.; Cha, H.-J. Crosstalk between Yap and TGFβ regulates SERPINE1 expression in mesenchymal lung cancer cells. Int. J. Oncol. 2021, 58, 111–121. [Google Scholar] [CrossRef] [PubMed]
- Higgins, C.E.; Tang, J.; Higgins, S.P.; Gifford, C.C.; Mian, B.M.; Jones, D.M.; Zhang, W.; Costello, A.; Conti, D.J.; Samarakoon, R.; et al. The genomic response to TGF-β1 dictates failed repair and progression of fibrotic disease in the obstructed kidney. Front. Cell Dev. Biol. 2021, 9, 678524. [Google Scholar] [CrossRef] [PubMed]
- Marquard, S.; Thomann, S.; Weiler, S.M.E.; Bissinger, M.; Lutz, T.; Sticht, C.; Tóth, M.; de la Torre, C.; Gretz, N.; Straub, B.K.; et al. Yes-associated protein (YAP) induces a secretome phenotype and transcriptionally regulates plasminogen activator inhibitor-1 (PAI-1) expression in hepatocarcinogenesis. Cell Commun. Signal. 2020, 18, 166. [Google Scholar] [CrossRef] [PubMed]
- Zanconato, F.; Cordenonsi, M.; Piccolo, S. YAP and TAZ: A signalling hub of the tumour microenvironment. Nat. Rev. Cancer 2019, 19, 454–464. [Google Scholar] [CrossRef] [PubMed]
- Tadeo, I.; Berbegall, A.P.; Escudero, L.M.; Alvaro, T.; Noguera, R. Biotensegrity of the extracellular matrix: Physiology, dynamic mechanical balance, and implications in oncology and mechanotherapy. Front. Oncol. 2014, 4, 39. [Google Scholar] [CrossRef] [PubMed]
- Yoshida, G.J. Regulation of heterogeneous cancer-associated fibroblasts: The molecular pathology of activated signaling pathways. J. Exp. Clin. Cancer Res. 2020, 39, 112. [Google Scholar] [CrossRef] [PubMed]
- Tsai, P.-J.; Lai, Y.-H.; Manne, R.K.; Tsai, Y.-S.; Sarbassov, D.; Lin, H.-K. Akt: A key transducer in cancer. J. Biomed. Sci. 2022, 29, 76. [Google Scholar] [CrossRef] [PubMed]
- Xue, G.; Hemmings, B.A. PKB/Akt-dependent regulation of cell motility. J. Natl. Cancer Inst. 2013, 105, 393–404. [Google Scholar] [CrossRef]
- Singh, S.P.; Paschke, P.; Tweedy, L.; Insall, R.H. AKT and SGK kinases regulate cell migration by altering Scar/WAVE complex activation and Arp2/3 complex recruitment. Front. Mol. Biosci. 2022, 9, 965921. [Google Scholar] [CrossRef] [PubMed]
- Tong, H.; Li, K.; Zhou, M.; Wu, R.; Yang, H.; Peng, Z.; Zhao, Q.; Luo, K.Q. Coculture of cancer cells with platelets increases their survival and metastasis by activating the TGFβ/Smad/PAI-1 and PI3K/AKT pathways. Int. J. Biol. Sci. 2023, 19, 4259. [Google Scholar] [CrossRef] [PubMed]
- Simone, T.M.; Higgins, S.P.; Archambeault, J.; Higgins, C.E.; Ginnan, R.G.; Singer, H.; Higgins, P.J. A small molecule PAI-1 functional inhibitor attenuates neointimal hyperplasia and vascular smooth muscle cell survival by promoting PAI-1 cleavage. Cell. Signal. 2015, 27, 923–933. [Google Scholar] [CrossRef] [PubMed]
- Czekay, R.-P.; Higgins, P.J. The SERPINE1/LRP1 axis at the crossroads of downstream signaling to cell motility. Trends Cell Mol. Biol. 2018, 13, 85–98. [Google Scholar]
- Degryse, B.; Neels, J.G.; Czekay, R.-P.; Aertgeerts, K.; Kamikubo, Y.-I.; Loskutoff, D.J. The low density lipoprotein receptor-related protein is a motogenic receptor for plasminogen activator inhibitor-1. J. Biol. Chem. 2004, 279, 22595–22604. [Google Scholar] [CrossRef] [PubMed]
- Daubriac, J.; Han, S.; Grahovac, J.; Smith, E.; Hosein, A.; Buchanan, M.; Basik, M.; Boucher, Y. The crosstalk between breast carcinoma-associated fibroblasts and cancer cells promotes Rho A-dependent invasion via IGF and PAI-1. Oncotarget 2017, 9, 10375–10387. [Google Scholar] [CrossRef] [PubMed]
- Peng, Y.; Kajiyama, H.; Yuan, H.; Nakamura, K.; Yoshihara, M.; Yokoi, A.; Fujikake, K.; Yasui, H.; Yoshikawa, N.; Suzuki, S.; et al. PAI-1 secreted from metastatic ovarian cancer cells triggers the tumor-promoting role of the mesothelium in a feedback loop to accelerate peritoneal dissemination. Cancer Lett. 2019, 442, 181–192. [Google Scholar] [CrossRef] [PubMed]
- Mashiko, S.; Kitatani, K.; Toyoshima, T.; Ichimura, A.; Dan, T.; Usui, T.; Ishibashi, M.; Shigeta, S.; Nagase, S.; Miyata, T.; et al. Inhibition of plasminogen activator inhigitor-1 is a potential therapeutic strategy in ovarian cancer. Cancer Biol. Ther. 2015, 16, 253–260. [Google Scholar] [CrossRef] [PubMed]
- Muratoglu, S.C.; Mikhailenko, I.; Newton, C.; Migliorini, M.; Strickland, D.K. Low density lipoprotein receptor-related protein 1 (LRP1) forms a signaling complex with platelet-derived growth factor receptor-beta in endosomes and regulates activationof the MAPK pathway. J. Biol. Chem. 2010, 285, 14308–14317. [Google Scholar] [CrossRef] [PubMed]
- Zhang, M.; Bajraszewski, N.; Wu, E.; Wang, H.; Moseman, A.P.; Dabora, S.L.; Griffin, J.D.; Kwiatkowski, D.J. PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J. Clin. Investig. 2007, 117, 730–738. [Google Scholar] [CrossRef] [PubMed]
- Cadamuro, M.; Nardo, G.; Indraccolo, S.; Dall’olmo, L.; Sambado, L.; Moserle, L.; Francescet, I.; Colledan, M.; Massani, M.; Stecc, T.; et al. Platelet-derived growth factor-D and Rho GTPases regulate recruitment of cancer-associated fibroblasts in cholangiocarcinoma. Hepatology 2013, 58, 1042–1053. [Google Scholar] [CrossRef] [PubMed]
- Ying, H.-Z.; Chen, Q.; Zhang, W.-Y.; Zhang, H.-H.; Ma, Y.; Zhang, S.-Z.; Fang, J.; Yu, C.-H. PDGF signaling pathway in hepatic fibrosis pathogenesis and therapeutics (review). Mol. Med. Rep. 2017, 16, 7879–7889. [Google Scholar] [CrossRef] [PubMed]
- Fingas, C.D.; Mertens, J.C.; Razumilava, N.; Bronk, S.F.; Sirica, A.; Gores, G.J. Targeting PDGFR-β in cholangiocarcinoma. Liver Int. 2012, 32, 400–409. [Google Scholar] [CrossRef] [PubMed]
- Matada, G.S.P.; Das, A.; Dhiwar, P.S.; Ghara, A. DDR1 and DDR2: A review on signaling pathway and small molecule inhibitors as an anticancer agent. Med. Chem. Res. 2021, 30, 535–551. [Google Scholar] [CrossRef]
- Zhang, X.; Hu, Y.; Pan, Y.; Xiong, Y.; Zhang, Y.; Han, M.; Dong, K.; Song, J.; Liang, H.; Ding, Z.; et al. DDR1 promotes hepatocellular carcinoma metastasis through recruiting PSD4 to ARF-6. Oncogene 2022, 41, 1821–1834. [Google Scholar] [CrossRef] [PubMed]
- Le, C.C.; Bennasroune, A.; Collin, G.; Hachet, C.; Lehrter, V.; Rioult, D.; Dedieu, S.; Morgani, H.; Appert-Collin, A. LRP-1 promotes colon cancer cell proliferation in 3D collagen matrices by mediating DDR1 endocytosis. Front. Cell Dev. Biol. 2020, 8, 412. [Google Scholar] [CrossRef]
- Alenchery, R.G.; Ajalik, R.E.; Jerreld, K.; Midekksa, F.; Zhong, S.; Alkatib, B.; Awad, H.A. PAI-1 mediates TGF-β1-induced myofibroblast activation in tenocytes via mTOR signaling. J. Orthop. Res. 2023, 41, 2163–2174. [Google Scholar] [CrossRef] [PubMed]
- Omori, K.; Hattori, N.; Senoo, T.; Takayama, Y.; Masuda, T.; Nakashima, T.; Iwamoto, H.; Fujitaka, K.; Hamada, H.; Kohno, N. Inhibition of plasminogen activator inhibitor-1 attenuates transforming growth factor-β-dependent epithelial mesenchymal transition and differentiation of fibroblasts to myofibroblasts. PLoS ONE 2016, 11, e0148969. [Google Scholar] [CrossRef] [PubMed]
- Wang, L.; Ly, C.M.; Ko, C.-Y.; Meyers, E.E.; Lawrence, D.A.; Bernstein, A.M. uPA binding to PAI-1 induces corneal myofibroblast differentiation on vitronectin. Investig. Ophthalmol. Vis. Sci. 2012, 53, 4765–4775. [Google Scholar] [CrossRef] [PubMed]
- Simone, T.M.; Longmate, W.M.; Law, B.K.; Higgins, P.J. Targeted inhibition of PAI-1 activity impairs epithelial migration and wound closure following cutaneous injury. Adv. Wound Care 2015, 4, 321–328. [Google Scholar] [CrossRef] [PubMed]
- Chen, S.; Morine, Y.; Tokuda, K.; Yamada, S.; Saito, Y.; Nishi, M.; Ikemoto, T.; Shimada, M. Cancer-associated fibroblast-induced M2-polarized macrophages promote hepatocellular carcinoma progression via the plasminogen activator inhibitor-1 pathway. Int. J. Oncol. 2021, 59, 59. [Google Scholar] [CrossRef] [PubMed]
- Bagordakis, E.; Sawazaki-Calone, I.; Macedo, C.C.; Carnielli, C.M.; de Oliveria, C.E.; Rodsiguez, P.C.; Rangel, A.L.; Dos Santos, J.N.; Risteli, J.; Graner, E.; et al. Secretome profiling of oral squamous ce;; carcinoma-associated fibroblasts reveals organization and disassembly of extracellular matrix and collagen metabolic process signatures. Tumour Biol. 2016, 37, 9045–9057. [Google Scholar] [CrossRef] [PubMed]
- Masuda, T.; Nakashima, T.; Namba, M.; Yamaguchi, K.; Sakamoto, S.; Horimasu, Y.; Miyamoto, S.; Iwamoto, H.; Fujitaka, K.; Miyata, Y.; et al. Inhibition of PAI-1 limits chemotherapy resistance in lung cancer through suppressing myofibroblast characteristics of cancer-associated fibroblasts. J. Cell Mol. Med. 2019, 23, 2984–2994. [Google Scholar] [CrossRef] [PubMed]
- Wang, S.; Pang, L.; Liu, Z.; Meng, X. SERPINE1 associated with remodeling of the tumor microenvironment in colon cancer progression: A novel therapeutic target. BMC Cancer 2021, 21, 767. [Google Scholar] [CrossRef] [PubMed]
- Yao, Q.; Chen, W.; Gao, F.; Wu, Y.; Zhou, L.; Xu, H.; Yu, J.; Zhu, X.; Wang, L.; Li, L.; et al. Characteristic analysis of featured genes associated with cholangiocarcinoma progression. Biomedicines 2023, 11, 847. [Google Scholar] [CrossRef] [PubMed]
- Song, G.; Shi, Y.; Meng, L.; Ma, J.; Huang, S.; Zhang, J.; Wu, Y.; Li, J.; Lin, Y.; Yang, S.; et al. Single-cell transcriptomic analysis suggests two molecularly distinct subtypes of intrahepatic cholangiocarcinoma. Nat. Commun. 2022, 13, 1641. [Google Scholar]
- Wang, H.; Vohra, B.P.S.; Zhang, Y.; Heuckeroth, R.O. Transcriptional profiling after bile duct ligation identifies PAI-1 as a contributor to cholestatis injury in mice. Hepatology 2005, 42, 1099–1108. [Google Scholar] [CrossRef] [PubMed]
- Bajou, K.; Noel, A.; Masson, G.V.; Brunner, N.; Holst-Hansen, C.; Skobe, M.; Fusenig, N.E.; Carmeliet, P.; Collen, D.; Foidart, J.M. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat. Med. 1998, 4, 923–928. [Google Scholar] [CrossRef] [PubMed]
- Gutierrez, L.S.; Schulman, A.; Brito-Robinson, T.; Noria, F.; Ploplis, V.A.; Castellino, F.J. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. Cancer Res. 2000, 60, 5839–5847. [Google Scholar] [PubMed]
- McMahon, G.A.; Petitclerc, E.; Stefansson, S.; Smith, E.; Wong, M.K.; Westrick, R.J.; Ginsburg, D.; Brooks, P.C.; Lawrence, D.A. Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J. Biol. Chem. 2001, 276, 33964–33968. [Google Scholar] [CrossRef] [PubMed]
- Stefansson, S.; Petitclerc, E.; Wong, M.K.; McMahon, G.A.; Brooks, P.C.; Lawrence, D.A. Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1. J. Biol. Chem. 2001, 276, 135–141. [Google Scholar] [CrossRef] [PubMed]
- Palmieri, D.; Lee, J.W.; Juliano, R.L.; Church, F.C. Plasminogen activator inhibitor-1 and -3 increase cell adhesion and motility of MDA-MB-435 breast cancer cells. J. Biol. Chem. 2022, 277, 40950–40957. [Google Scholar] [CrossRef] [PubMed]
- Providence, K.M.; White, L.A.; Tang, J.; Gonclaves, T.J.; Staiano-Coico, L.; Higgins, P.J. Epithelial monolayer wounding stimulates binding of USF-1 to an E-box motif in the plasminogen activator inhibitor type 1 gene. J. Cell Sci. 2022, 115 Pt 19, 3767–3777. [Google Scholar] [CrossRef]
- Al-Fakhri, N.; Chavakis, T.; Schmidt-Woll, T.; Huang, B.; Cherian, S.M.; Bobryshev, Y.V.; Lord, R.S.A.; Katz, N.; Preissner, K.T. Induction of apoptosis in vascular cells by plasminogen activator inhititor-1 and high molecular weight kininogen correlates with their anti-adhesive properties. Biol. Chem. 2023, 384, 423–435. [Google Scholar]
- Stefansson, S.; Lawrence, D.A. Old dogs and new tricks: Proteases, inhibitors, and cell migration. Sci. STKE 2003, 2003, pe24. [Google Scholar] [CrossRef] [PubMed]
- Czekay, R.-P.; Loskutoff, D.J. Plasminogen activator inhibitors regulate cell adhesion through a uPAR-dependent mechanism. J. Cell. Physiol. 2009, 220, 655–663. [Google Scholar] [CrossRef] [PubMed]
- Deng, G.; Curriden, S.A.; Hu, G.; Czekay, R.-P.; Loskutoff, D.J. Plasminogen activator inhibitor-1 regulates cell adhesion by binding to the somatomedin B domain of vitronectin. J. Cell. Physiol. 2001, 189, 23–33. [Google Scholar] [CrossRef] [PubMed]
- Kjoller, L.; Kanse, S.M.; Kirkegaard, T.; Rodenburg, K.W.; Ronne, E.; Goodman, S.L.; Preissner, K.T.; Ossowski, P.; Andreasen, P.A. Plaminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp. Cell Res. 1997, 232, 420–429. [Google Scholar] [CrossRef] [PubMed]
- Loskutoff, D.J.; Curriden, S.A.; Hu, G.; Deng, G. Regulation of cell adhesion by PAI-1. APMIS 1999, 107, 54–61. [Google Scholar] [CrossRef] [PubMed]
- Munoz-Galvan, S.; Rivero, M.; Peinado-Serrano, J.; Martinez-Perez, J.; Fernandez-Fernandez, M.C.; Ortiz, M.J.; Garcia-Heredia, J.M.; Carnero, A. PAI1 is a marker of bad prognosis in rectal cancer but predicts a better response to treatment with PIM inhibitor AZD1208. Cell 2020, 9, 1071. [Google Scholar] [CrossRef] [PubMed]
- Abe, J.; Urano, T.; Konno, H.; Erhan, Y.; Tanaka, T.; Nishino, N.; Takada, A.; Nakamura, S. Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size. Cancer 2000, 86, 2602–2611. [Google Scholar] [CrossRef]
- Mignatti, P.; Rifkin, D.B. Nonenzymatic interactions between proteinases and the cell surface: Novel roles in normal and malignant cell physiology. Adv. Cancer Res. 2000, 78, 103–157. [Google Scholar] [PubMed]
- Higgins, P.J.; Ryan, M.P. Biochemical localization of the transformation-sensitive 52 kDa (p52) protein to the substratum contact regions of cultured rat fibroblasts. Biochem. J. 1989, 257, 173–182. [Google Scholar] [CrossRef]
- Seiffert, D.; Ciambrone, G.; Wagner, N.V.; Binder, B.R.; Loskutoff, D.J. The somatomedin B domain of vitronectin. Structural requirements for the binding and stabilization of active type 1 plasminogen activator inhibitor. J. Biol. Chem. 1994, 269, 2659–2666. [Google Scholar] [CrossRef] [PubMed]
- Lawrence, D.A.; Palaniappan, S.; Stefansson, S.; Olson, S.T.; Francis-Chmura, A.M.; Shore, J.D.; Ginsburg, D. Characterization of the binding of different conformational forms of plasminogen activator inhibitor-1 to vitronectin. Implications for the regulation of pericellular proteolysis. J. Biol. Chem. 1997, 272, 7676–7680. [Google Scholar] [CrossRef] [PubMed]
- Andreasen, P.A.; Egelund, R.; Petersen, H.H. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell. Mol. Life Sci. 2000, 57, 25–40. [Google Scholar] [CrossRef]
- Czekay, R.-P.; Aertgeerts, K.; Curriden, S.A.; Loskutoff, D.J. Plasminogen activator-1 detaches cells from extracellular matrices by inactivating integrins. J. Cell Biol. 2003, 160, 781–791. [Google Scholar] [CrossRef] [PubMed]
- Pepper, M.S.; Sappino, A.P.; Montesano, R.; Orci, L.; Vassalli, J.D. Plasminogen activator inhibitor-1 is induced in migrating endothelial cells. J. Cell. Physiol. 1992, 153, 129–139. [Google Scholar] [CrossRef] [PubMed]
- Seebacher, T.; Manske, M.; Zoller, J.; Crabb, J.; Bade, E.G. The EFG-inducible protein EIP-1 of migrating normal and malignant rat liver epithelial cells is identical to plasminogen activator inhibitor 1 and is a component of the ECM migration tracks. Exp. Cell Res. 1992, 202, 504–507. [Google Scholar] [CrossRef] [PubMed]
- Providence, K.M.; Higgins, S.P.; Mullen, A.; Battista, A.; Samarakoon, R.; Higgins, C.E.; Wilkins-Port, C.E.; Higgins, P.J. SERPINE1 (PAI-1) is deposited into keratinocyte migration “trails” and required for optimal monolayer wound repair. Arch. Dermatol. Res. 2008, 300, 303–310. [Google Scholar] [CrossRef] [PubMed]
- Ciambrone, G.J.; McKeown-Longo, P.J. Plasminogen activator inhibitor type 1 stabilizes vitronectin-dependent adhesions in HT-1080 cells. J. Cell Biol. 1990, 111 Pt 1, 2183–2195. [Google Scholar] [CrossRef] [PubMed]
- Lobov, S.; Ranson, M. Molecular competition between plasminogen activator inhibitors type-1 and -2 for urokinase: Implications for cellular proteolysis and adhesion in cancer. Cancer Lett. 2011, 303, 118–127. [Google Scholar] [CrossRef] [PubMed]
- Chapman, H.A. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr. Opin. Cell Biol. 1997, 9, 14–24. [Google Scholar] [CrossRef] [PubMed]
- De Lorenzi, V.; Ferraris, G.M.S.; Madsen, J.B.; Lupia, M.; Andreasen, P.A.; Sidenius, N. Urokinase links plasminogen activation and cell adhesion by cleavage of the RGD motif in vitronectin. Embo Rep. 2016, 17, 982–998. [Google Scholar] [CrossRef] [PubMed]
- Providence, K.M.; Kutz, S.M.; Staiano-Coico, L.; Higgins, P.J. PAI-1 gene expression is regionally induced in wounded epithelial cell monolayers and required for injury repair. J. Cell. Physiol. 1995, 182, 269–280. [Google Scholar] [CrossRef]
- Brooks, T.D.; Wang, S.W.; Brunner, N.; Charlton, P.A. XR5967, a novel modulator of plasminogen activator inhibitor-1 activity, suppresses tumor cell invasion and angiogenesis in vitro. Anticancer Drugs 2004, 15, 37–44. [Google Scholar] [CrossRef] [PubMed]
- Humphries, B.A.; Buschhaus, J.M.; Chen, Y.-C.; Haley, H.R.; Qyli, T.; Chiang, B.; Shen, N.; Rajendran, S.; Cutter, A.; Cheng, Y.-H.; et al. Plasminogen activator inhibitor 1 (PAI1) promotes actin cytoskeleton reogranization and glycolytic metabolism in triple-negative breast cancer. Mol. Cancer Res. 2019, 17, 1142–1154. [Google Scholar] [CrossRef] [PubMed]
- Chazaud, B.; Ricous, R.; Christov, C.; Plonquet, A.; Gherardi, R.K.; Barlovatz-Meimon, G. Promigratory effect of plasminogen activator inhibitor-1 on invasive breast cancer cell populations. Am. J. Pathol. 2002, 160, 237–246. [Google Scholar] [CrossRef] [PubMed]
- Ryan, M.P.; Borenfreund, E.; Higgins, P.J. Cytoarchitectural analysis of epithelial sheets formed in vitro by hepatic tumor cells possessing defined intermediate-sized filament cytoskeletal abnormalities. Am. J. Path. 1989, 134, 447–456. [Google Scholar] [PubMed]
- Fischer, H.P.; Altmannsberger, M.; Weber, K.; Osborn, M. Keratin polypeptides in malignant epithelial liver tumors. Differential diagnostic and histologic aspects. Am. J. Path. 1987, 127, 530–537. [Google Scholar] [PubMed]
- Higgins, P.J.; Ryan, M.P. Identification of the 52 kDa cytoskeletal-like protein of cytochalasin D-stimulated normal rat kidney (NRK/CD) cells as substrate-associated glycoprotein p52 [plasminogen-activator inhibitor type-1 (PAI-1)]. Expression of p52 (PAI-1) in NRK/CD cells is regulated at the level of mRNA abundance. Biochem. J. 1992, 284, 433–439. [Google Scholar] [PubMed]
- Higgins, P.J.; Ryan, M.P.; Jelley, D.M. p52PAI-1 gene expression is butyrate-induced flat revertants of v-ras-transformed rat kidney cells: Mechanism of induction and involvement in the morphological response. Biochem. J. 1997, 321, 431–437. [Google Scholar] [CrossRef]
- Placencio, V.; DeClerck, Y.A. Plasminogen activator inhibitor in cancer: Rationale and insight for future therapeutic testing. Cancer Res. 2015, 75, 2969–2974. [Google Scholar] [CrossRef] [PubMed]
- Kubala, M.H.; DeClerck, Y.A. The plasminogen activator inhibitor-1 paradox in cancer: A mechanistic understanding. Cancer Metast. Rev. 2019, 38, 483–492. [Google Scholar] [CrossRef] [PubMed]
- Fang, H.; Placencio, V.R.; DeClerck, Y.A. Protumorigenic activity of plasminogen activator inhibitor-1 through an antiapoptotic function. J. Natl. Cancer Inst. 2012, 104, 1470–1484. [Google Scholar] [CrossRef] [PubMed]
- Fang, H.; DeClerck, Y.A. Targeting the tumor microenvironment: From understanding pathways to effective clinical trials. Cancer Res. 2013, 73, 4965–4977. [Google Scholar] [CrossRef] [PubMed]
- Yahata, T.; Ibrahim, A.A.; Hirano, K.-i.; Muguruma, Y.; Naka, K.; Hozumi, K.; Vaughan, D.E.; Miyata, T.; Ando, K. Targeting of plasminogen activator inhibitor-1 activity promotes elimination of chronic myeloid leukemia stem cells. Haematologica 2021, 106, 483–494. [Google Scholar] [CrossRef] [PubMed]
- Bergheim, I.; Guo, L.; Davis, M.A.; Duveau, I.; Arteel, G.E. Critical role of plasminogen activator inhibitor-1 in cholestatic liver injury and fibrosis. J. Pharmacol. Exp. Therapeut. 2006, 316, 592–600. [Google Scholar] [CrossRef] [PubMed]
- Wang, H.; Zhang, Y.; Heuckeroth, R.O. Pai-1 deficiency reduces liver fibrosis after bile duct ligation in mice through activation of tPA. FEBS Lett. 2007, 581, 3098–3104. [Google Scholar] [CrossRef] [PubMed]
- Noguchi, R.; Kaji, K.; Namisaki, T.; Moriya, K.; Kawaratani, H.; Kitade, M.; Takaya, H.; Aihara, Y.; Douhara, A.; Asada, K.; et al. Novel oral plasminogen activator inhibitor-1 inhibitor TM5275 attenuates hepatic fibrosis under metabolic syndrome via suppression of activated hepatic stellate cells in rats. Mol. Med. Rep. 2020, 22, 2948–2956. [Google Scholar] [CrossRef] [PubMed]
- Nam, D.-E.; Seong, H.C.; Hahn, Y.S. Plasminogen activator inhibitor-1 and oncogenesis in liver disease. J. Cell. Signal. 2021, 2, 221–227. [Google Scholar] [PubMed]
- Flevaris, P.; Vaughan, D. The role of plasminogen activator inhibitor type-1 in fibrosis. Semin. Thromb. Hemost. 2017, 143, 169–177. [Google Scholar] [CrossRef] [PubMed]
- Lijnen, H.R. Pleotropic functions of plasminogen activator inhibitor-1. J. Thromb. Haemost. 2004, 3, 35–45. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Czekay, R.-P.; Higgins, C.E.; Aydin, H.B.; Samarakoon, R.; Subasi, N.B.; Higgins, S.P.; Lee, H.; Higgins, P.J. SERPINE1: Role in Cholangiocarcinoma Progression and a Therapeutic Target in the Desmoplastic Microenvironment. Cells 2024, 13, 796. https://doi.org/10.3390/cells13100796
Czekay R-P, Higgins CE, Aydin HB, Samarakoon R, Subasi NB, Higgins SP, Lee H, Higgins PJ. SERPINE1: Role in Cholangiocarcinoma Progression and a Therapeutic Target in the Desmoplastic Microenvironment. Cells. 2024; 13(10):796. https://doi.org/10.3390/cells13100796
Chicago/Turabian StyleCzekay, Ralf-Peter, Craig E. Higgins, Hasan Basri Aydin, Rohan Samarakoon, Nusret Bekir Subasi, Stephen P. Higgins, Hwajeong Lee, and Paul J. Higgins. 2024. "SERPINE1: Role in Cholangiocarcinoma Progression and a Therapeutic Target in the Desmoplastic Microenvironment" Cells 13, no. 10: 796. https://doi.org/10.3390/cells13100796